|
|
|
Volumn 17, Issue 1, 2005, Pages 5-6
|
|
Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PROTEINASE INHIBITOR;
PYRIDINE DERIVATIVE;
PYRONE DERIVATIVE;
RITONAVIR;
TIPRANAVIR;
ARTICLE;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG COMBINATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
VIRUS LOAD;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIALS, PHASE III;
DRUG THERAPY, COMBINATION;
HIV INFECTIONS;
HIV PROTEASE INHIBITORS;
HUMANS;
PYRIDINES;
PYRONES;
RANDOMIZED CONTROLLED TRIALS;
RITONAVIR;
VIRAL LOAD;
|
|
EID: 14744275537
PISSN: 10431543
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
